Booster Therapeutics has announced its inception to develop a new class of proteasome activator medicines for ...

KeyBioscience and Eli Lilly have extended their partnership to develop a new class of treatments for obesity and associated ...

At CPHI Europe, Angela Vollstedt, global director of Cell & Gene Therapies at Novartis discussed scale up strategies for cell ...

High-concentration monoclonal antibodies (mAbs) are gaining prominence given the compliance and cost advantages.

Germany-based Merck KGaA has announced the launch of a new €290m ($317.6m) biosafety testing facility in Rockville, Maryland, ...

Whilst the events do not outline any new safety risks, the data gives a new understanding of the link between oncogenesis and ...

According to Lancet Public Health, the incidence of probable food allergy more than doubled in England between 2008 and 2018.

Eli Lilly and insitro said the deals offers a “new paradigm” for collaborations between major pharmaceutical companies and ...

As a risk factor for future serious health conditions, the early prevention, detection and management of type 2 diabetes are ...